Clinical Studies of Silymarin as a Protective Agent Against Liver Damage Caused by Anti-TB Drugs, Methotrexate, and in Cases of Chronic Hepatitis C and Diabetes Mellitus
Pharmacognosy Journal · 04.05.2022 · 14 (2) · 358-368
DOI: 10.5530/pj.2022.14.46 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacognosy Journal, online erschienen am 04.05.2022. Verfasst von Jimenez-Arellanes Maria Adelina. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Adelina, J. M. (2022). Clinical Studies of Silymarin as a Protective Agent Against Liver Damage Caused by Anti-TB Drugs, Methotrexate, and in Cases of Chronic Hepatitis C and Diabetes Mellitus. Pharmacognosy Journal, 14(2), 358-368. https://doi.org/10.5530/pj.2022.14.46
Vancouver
Adelina JM. Clinical Studies of Silymarin as a Protective Agent Against Liver Damage Caused by Anti-TB Drugs, Methotrexate, and in Cases of Chronic Hepatitis C and Diabetes Mellitus. Pharmacognosy Journal. 2022;14(2):358-368. doi:10.5530/pj.2022.14.46
BibTeX
@article{Adelina2022,
author = {Adelina, Jimenez-Arellanes Maria},
title = {Clinical Studies of Silymarin as a Protective Agent Against Liver Damage Caused by Anti-TB Drugs, Methotrexate, and in Cases of Chronic Hepatitis C and Diabetes Mellitus},
journal = {Pharmacognosy Journal},
year = {2022},
volume = {14},
number = {2},
pages = {358--368},
doi = {10.5530/pj.2022.14.46}
}
EUVIMED